ArticleMethods in molecular biology (Clifton, N.J.)2022
Macroscopic Fluorescence Lifetime Imaging for Monitoring of Drug-Target Engagement.
Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Defining the optimal imaging time point for fluorescence-lifetime-based tumor identification using the non-targeting near-infrared dye indocyanine green and post-processed high-dynamic-range images.Biomedical optics express · 2026Article
- Enhancing Fluorescence Lifetime Imaging With Differential Transformer.Journal of biophotonics · 2026Article
- High-speed wide-field fluorescence lifetime imaging for intraoperative tumor visualization and in vivo multiplexing.Biomedical optics express · 2025Article
- Depth-Resolved Macroscopic Fluorescence Lifetime Imaging via High-Spatial-Frequency Structured Illumination.bioRxiv : the preprint server for biology · 2025Article
- Design and characterization of an optical phantom for mesoscopic multimodal fluorescence lifetime imaging and optical coherence elastography.Biomedical optics express · 2025Article
- Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent advances in ratiometric fluorescence imaging of enzyme activity in vivo.Current opinion in chemical biology · 2024Review
- Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments.bioRxiv : the preprint server for biology · 2024Article
- Applications of machine learning in time-domain fluorescence lifetime imaging: a review.Methods and applications in fluorescence · 2024Review
- Multiplexed near infrared fluorescence lifetime imaging in turbid media.Journal of biomedical optics · 2024Article
- In vivo quantitative FRET small animal imaging: Intensity versus lifetime-based FRET.Biophysical reports · 2023Article
- Article
- 3D k-space reflectance fluorescence tomography via deep learning.Optics letters · 2022Article
- Multiplexed non-invasive tumor imaging of glucose metabolism and receptor-ligand engagement using dark quencher FRET acceptor.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Precision medicine promises to improve therapeutic efficacy while reducing adverse effects, especially in oncology. However, despite great progresses in recent years, precision medicine for cancer treatment is not always part of routine care. Indeed, the ability to specifically tailor therapies to distinct patient profiles requires still significant improvements in targeted therapy development as well as decreases in drug treatment failures. In this regard, preclinical animal research is fundamental to advance our understanding of tumor biology, and diagnostic and therapeutic response. Most importantly, the ability to measure drug-target engagement accurately in live and intact animals is critical in guiding the development and optimization of targeted therapy. However, a major limitation of preclinical molecular imaging modalities is their lack of capability to directly and quantitatively discriminate between drug accumulation and drug-target engagement at the pathological site. Recently, we have developed Macroscopic Fluorescence Lifetime Imaging (MFLI) as a unique feature of optical imaging to quantitate in vivo drug-target engagement. MFLI quantitatively reports on nanoscale interactions via lifetime-sensing of Förster Resonance Energy Transfer (FRET) in live, intact animals. Hence, MFLI FRET acts as a direct reporter of receptor dimerization and target engagement via the measurement of the fraction of labeled-donor entity undergoing binding to its respective receptor. MFLI is expected to greatly impact preclinical imaging and also adjacent fields such as image-guided surgery and drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.